20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Credit Suisse has initiated coverage on Eli Lilly And Co (NYSE:LLY) with an Outperform rating and a price target of $395.
- Management has delivered a remarkable performance against a challenging backdrop. However, with the stock at an all-time high valuation, the key question is whether it can continue this momentum.
- The analysts are optimistic and believe that Eli Lilly has industry-leading growth in the short- and long-term, unhampered by loss of exclusivity (LOE).
- Related: Eli Lilly Says Q3 Earnings Supported By Key Products and Volume, Cuts FY22 Outlook.
- Credit Suisse notes some turbulence if Mounjaro cannot hit short-term quarterly numbers, with supply concerns, but in the long term, it is expected to be one of the most valuable drugs in Pharma.
- Several investors remain offside given the binary donanemab TRAILBLAZER-2 Alzheimer’s Phase 3 data expected in mid-2023, but analysts think the setup is skewed to the upside.
- The analyst believes the Street is underappreciating the obesity market size given the impressive data and favorable reimbursement with Wegovy. Donanemab (Alzheimer’s) should continue to dominate the headlines.
- Price Action: LLY shares are down 0.23% at $359.93 on the last check Friday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!